Background: APX001A is an antifungal agent that targets a novel pathway-glycosylphosphatidylinositol glycolipid biosynthesis. It has been shown to be effective against a variety of fungal species, including Candida spp., Aspergillus spp. and other filamentous fungi.
Introduction
Glycosylphosphatidylinositol (GPI) glycolipid biosynthesis is an essential cellular process for both yeasts and moulds. GPI glycolipids perform post-translational modifications to many fungal proteins that are involved in cell wall organization, adhesion to substrates and immune evasion. Without this modification, many proteins would not localize to the cell surface, destabilizing the fungal cell wall and compromising cell growth and survival. [1] [2] [3] As such, GPI biosynthesis represents an attractive, novel antifungal drug target.
APX001A (formerly E1210, Amplyx) is a small molecule inhibitor of GPI biosynthesis. It functions by targeting and inhibiting an enzyme of the GPI biosynthesis pathway, Gwt1p. APX001A exhibits potent antifungal activity against Candida species and Aspergillus species, as well as various moulds including Fusarium solani, Lomentospora prolificans, Purpureocillium lilacinum, Cladosporium spp. and Exophiala dermatitidis. It has also shown potent activity against isolates that are azole and/or echinocandin resistant. [4] [5] [6] [7] Here, we evaluate the in vitro susceptibility of emerging pathogen Candida auris to APX001A. This pathogen is of particular importance because it is associated with high mortality, is emerging as a source of hospital-acquired infection around the world and can be MDR.
8-10
Methods One hundred C. auris isolates from various countries were selected for this study. 10 They were chosen both for their variable susceptibilities to other antifungal agents and to represent the four known international clades. This collection included six isolates with elevated MICs of one or more echinocandins and 24 isolates with elevated MICs of amphotericin B. Included are two isolates that are resistant to all three antifungal drug classes (Table 1) . Susceptibility testing via broth microdilution was performed as outlined by the CLSI. 11 APX001A powder was obtained from the manufacturer and a stock solution was prepared in DMSO. The range of APX001A concentrations tested was 0.0005-0.25 mg/L. Quality control isolates Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258 were included on each day of testing and remained within the range reported by other laboratories and varied only by one to two dilutions over the course of the study. 6 Plates were read visually after 24 h of incubation and the MIC was defined as the well with a 50% decrease in growth compared with the drug-free control well.
Results
MICs of APX001A ranged from ,0.005 to 0.015 mg/L (Figure 1 ). The overall mode was ,0.005 mg/L and the MIC 50 and MIC 90 were 0.002 and 0.008 mg/L, respectively. APX001A showed strong activity against all four clades of C. auris with little variation in activity between the clades.
The distribution of MICs of the echinocandins for the same collection ranged from 0.03 to 
Discussion
This report describes in vitro susceptibilities of a large diverse collection of C. auris isolates to the novel antifungal agent APX001A. This drug is on track for Phase 2 trials in the treatment of both invasive aspergillosis and invasive candidiasis. While there are no interpretative breakpoints for C. auris against APX001A, the MICs obtained here indicate excellent in vitro activity against the entire collection and are consistent with the MICs for other species of Candida.
6 No meaningful differences in activity were observed between isolates from different clades, indicating that genetic diversity arising between geographically distinct isolates does not influence the activity of the compound. These findings corroborate what has been shown with a limited collection of C. auris isolates in vitro and in a murine model of disseminated candidiasis. 12 Importantly there are no differences in MICs for isolates that are known to be resistant to one or more antifungal drugs. Even when isolates were resistant to all three antifungal classes, APX001A showed potent activity (Table 1 ). This suggests that while different mechanisms of resistance are functioning in these isolates, they are not meaningful in terms of APX001A activity. Overall, this compound shows encouraging activity against C. auris. Activity of APX001A against Candida auris JAC
